Information About Vaxzevria

Disclaimer: The information on this page is intended for Healthcare Professionals only.

A Conditional Marketing Authorisation (CMA) has been granted in the EU for the product Vaxzevria for active immunisation of individuals aged 18 years and older for the prevention of coronavirus disease 2019 (COVID-19). During the pandemic, Vaxzevria may also be distributed in packaging with the name COVID‑19 Vaccine AstraZeneca.

You can find more information here (https://www.ema.europa.eu/en).

Report an Adverse Event via the Health Products Regulatory Authority Website

If you are concerned about an adverse event, it can be reported via the Health Products Regulatory Authority website, (https://www.hpra.ie/homepage/about-us/report-an-issue/covid-19-vaccine-adverse-reaction).

This link will take you to another website. AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.

AstraZeneca Vaccine Reporting